Announcement on the 2019 profit distribution plan.
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2020-005
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2019 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
- Distribution Ratio per Share: Cash Dividend 3.0 Yuan (Tax Included) for Every 10 Shares. No bonus shares will be distributed and no CPF capitalization will be made in 2019.
- This profit distribution is based on the total share capital registered on the equity registration date of the implementation of the equity distribution, and the specific date will be specified in the equity distribution implementation announcement.
- If the total share capital of the company changes before the equity registration date for the implementation of the equity distribution, it is proposed to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly, and the specific adjustment will be announced separately.
- Brief description of this year's profit distribution plan: At present, the company is in the stage of accelerated development. In 2020, the company will accelerate the promotion of Guizhou peak daily production of 4500 tons of cement clinker new dry cement production line off-site technical transformation (with waste heat power generation) project, peak pharmaceutical Jinxi production base annual output of 2 billion pieces of solid preparation project, Anhui Zhongwang phase II technical transformation project, new Beika chemical technical transformation project and other projects under construction. In addition, Spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor drug "DPT" has entered the clinical stage, the need to increase research and development investment. The development of the above-mentioned business requires large financial support. The content of
1. profit distribution plan
was audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of the company in 2019 was ,724,688,055.43 yuan. The net profit of the parent company's accounting statement ,267,306,832.98 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 26,730,683.30 yuan, plus undistributed profit 1,014,878,186.69 yuan at the beginning of the year, minus 2018 annual cash dividend 103,225,148.40 yuan, and the distributable profit for this year is 1,152,229,187.97 yuan.
Company plans to make cash distribution in 2019 , based on ,344,083, 828 shares at the end of 2019 , with cash dividends 3.0 yuan (tax included) for every 10 shares, and the total cash dividends to all shareholders registered on the date of record are 103,225,148.40 yuan (tax included).
No CPF conversion to share capital in 2019 .
If the total share capital of the Company changes due to the conversion of convertible bonds/ repurchase of shares / equity incentive grant of share repurchase and cancellation / major asset restructuring share repurchase and cancellation during the period from the date of disclosure of this announcement to the date of registration of equity distribution, the Company intends to maintain the distribution ratio per share and adjust the total distribution accordingly. If the subsequent total share capital changes, the specific adjustment will be announced separately.
This profit distribution plan still needs to be submitted to the general meeting of shareholders for consideration. During the reporting period of
, the net profit attributable to the shareholders of the listed company in the consolidated statement of the company was 724,688,055.43
yuan, the accumulated undistributed profit of the parent company was1,152,229,187.97 yuan, and the total cash dividend to be distributed by the listed company was 103,225,148.40 yuan (including tax), the proportion of net profit attributable to shareholders of listed companies this year is lower than 30% . The specific reasons are as follows: At present, the company is in the stage of accelerated development and has many construction projects. In 2020
, the company will continue to accelerate the construction of the project( estimated investment is 6.5 .2 billion ) of the new dry cement production line with a daily output of 4500 tons of cement clinker in Guizhou Huangping Jianfeng Cement Co., Ltd; the holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. Jinxi Production Base produces 20 .6 billion pieces of solid preparation project ( is expected to invest 50146 million yuan ) ; The holding subsidiary Anhui zhongwang pharmaceutical co., ltd. phase ii technological transformation project ( estimated total investment is 17500 .06 million yuan ) ; the construction and renovation of the technical renovation project ( is expected to invest 13274.25 .12 million yuan ) and other projects under construction by the end of 2019 , the above-mentioned projects have invested 4.91 .8 billion yuan. In addition, Jianfeng Pharmaceutical has a number of new drugs in various stages of research and development. The new anti-tumor drug "DPT " has entered the clinical stage. Jianfeng Pharmaceutical and its subsidiaries Zhejiang Erying Pharmaceutical Co., Ltd. and Zhejiang Jianfeng Yien Biotechnology Co., Ltd. will further increase product research and development and introduction, and need to increase research and development investment. The development of the above-mentioned business requires large financial support. 3. the decision-making procedure performed by the company
(I) the convening, deliberation and voting of the board meeting
2020
April# December August24 , the company held the 14th meeting of the 10th board of 131 by combining on-site and communication voting. the company currently has eight directors, all of whom attended the meeting in person, comply with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the profit distribution plan of the company 2019 was deliberated and approved by 8 votes, 0 votes against, and 0 votes abstention. The board of directors of intends to submit the plan to the annual general meeting of shareholders of 2019 for deliberation. When the company holds the general meeting of shareholders, it will provide investors with convenient conditions for online voting.
(II) Independent Director's OpinionThe independent director of the company expressed the following opinions on the company's 2019
annual profit distribution plan:1
, agreeing that the company will pay a cash dividend of 3.0
yuan (including tax) for every10 shares based on 2019 year-end share capital ,344,083, 828 shares, the total amount of cash dividends distributed to all shareholders registered on the date of record is 103,225,148.40 yuan (including tax), 2019 year will not be converted into share capital. , the profit distribution plan is based on the actual operating results and financial situation of the Company
2019, combined with the actual needs of the Company's future business development. Retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors are of the opinion that the profit distribution plan complies with the relevant provisions of the Articles of Association for profit distribution and the actual operating conditions of the Company. 3 , the company's board of directors considered and approved the above profit distribution plan. The Independent Directors are of the opinion that the convening, convening and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the Articles of Association of the Company, and are legal and effective; and agree to submit the proposal to the Company's
2019Annual General Meeting for consideration. (III) the opinions of the board of supervisors
2020, the company held the 184 meeting of the 9th 183 of the 9th board of supervisors. the company currently has five supervisors, all of whom attended the meeting in person, which conforms to the relevant provisions of the company law and the articles of association, and the resolution made is legal and effective. The meeting was presided over by Mr. Chen Tianci, Chairman of the Board of Supervisors. After deliberation and voting, the company's profit distribution plan for the year 2019 was deliberated and approved with 5 votes, 0 votes against, and 0 abstentions. Agree to submit to the general meeting of shareholders for consideration. The Board of Supervisors believes that: the company's 2019 profit distribution plan complies with the relevant provisions of the Articles of Association; the description of the profit distribution plan is objective and true, the decision-making procedures are in compliance, and meet the interests of all shareholders and the company's production and operation needs; No company profit distribution and cash dividend decisions were found to damage the legitimate rights and interests of shareholders.
4. Related Risk Reminder This profit distribution plan must be submitted to the company's 2019
annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
April
28, 2002
More information
The company's "three" cultivation through the stage of acceptance
Since November 2015 was included in the second batch of "three" cultivation pilot enterprises in Zhejiang Province, the company has carried out a series of related work in depth. On October 19, the implementation of the company's "three" cultivation project from January 2016 to September 2017 passed the phased acceptance organized by Jinhua Economic and Information Commission and Jinhua Finance Bureau. According to the requirements of the "three" cultivation pilot enterprise responsibility letter signed with Zhejiang Province, Jinhua City and Wucheng District, as of the end of September 2017, the company has invested 16.0772 million yuan in related projects, and has achieved remarkable results in improving management, improving automation and informatization level. For example, after the digital system of quality and cost control in the plant extraction workshop of Jianfeng Health Technology Company is put into use, the whole production process can be controlled and traceable, the product quality is more stable, the production safety is effectively guaranteed, the "three wastes" emission is greatly reduced, and the product cost is reduced by 20%. The electronic label system of the pharmaceutical company automatically addresses and accurately locates the drugs in and out of the warehouse, which reduces the error rate of the out and into the warehouse, and the location management can automatically display the information such as the location and quantity of the drugs, which improves the work efficiency of the warehouse logistics and effectively reduces the management cost. The pharmaceutical company's sales management information system integrates sales management, warehouse management, customer management, statistical analysis and other modules, realizes drug sales management and control functions according to the requirements of GMP and GSP specifications, and analyzes drug regions and sales volume through big data, which will judge drug consumption trends faster and more accurately and improve the accuracy of the company's drug sales decisions. Health
2020
07-31
The company's "three" cultivation through the stage of acceptance
Since November 2015 was included in the second batch of "three" cultivation pilot enterprises in Zhejiang Province, the company has carried out a series of related work in depth. On October 19, the implementation of the company's "three" cultivation project from January 2016 to September 2017 passed the phased acceptance organized by Jinhua Economic and Information Commission and Jinhua Finance Bureau. According to the requirements of the "three" cultivation pilot enterprise responsibility letter signed with Zhejiang Province, Jinhua City and Wucheng District, as of the end of September 2017, the company has invested 16.0772 million yuan in related projects, and has achieved remarkable results in improving management, improving automation and informatization level. For example, after the digital system of quality and cost control in the plant extraction workshop of Jianfeng Health Technology Company is put into use, the whole production process can be controlled and traceable, the product quality is more stable, the production safety is effectively guaranteed, the "three wastes" emission is greatly reduced, and the product cost is reduced by 20%. The electronic label system of the pharmaceutical company automatically addresses and accurately locates the drugs in and out of the warehouse, which reduces the error rate of the out and into the warehouse, and the location management can automatically display the information such as the location and quantity of the drugs, which improves the work efficiency of the warehouse logistics and effectively reduces the management cost. The pharmaceutical company's sales management information system integrates sales management, warehouse management, customer management, statistical analysis and other modules, realizes drug sales management and control functions according to the requirements of GMP and GSP specifications, and analyzes drug regions and sales volume through big data, which will judge drug consumption trends faster and more accurately and improve the accuracy of the company's drug sales decisions. Health
2020
07-30
Yunnan Jianfeng supplies cement directly to Wa State of Myanmar
Yunnan Jianfeng Cement Company not only consolidates the original domestic market, but also gives full play to the location advantages of the three counties (Lancang, Menglian and Ximeng) close to the border to continuously expand the foreign market. Recently, the marketing department took the initiative to step out of the country from the Mangxin port in Menglian County and successfully sold "Jianfeng" brand cement to the newly planned Jinhua Xiaozunhe Island Development Zone in the Wa State of Myanmar. With the rapid development of China's economy in recent years, Myanmar has also increased the development of the China-Myanmar border area year by year. In order to attract more Chinese tourists to spend in transit, the Wa State Government of Myanmar has planned the Jinhua Xiaozunhe Island Development Zone near China's Menglian Mangxin Port. After the development zone is completed, it will mainly focus on gambling, business hotels, and border trade. There is an estimated demand for about 80000 tons of cement. When Yunnan Jianfeng marketing personnel learned of the news, they went deep into the development zone many times to understand the situation and had extensive contact with customers. With the good reputation of Jianfeng Cement in southwest Yunnan in recent years, they successfully signed a supply contract with a commercial mixing station in the development zone. At present, Yunnan Jianfeng has directly supplied 1200 tons of cement through Mangxin Port, and is expected to win 80% of the cement supply business of the development project. The initiative of "Belt and Road Initiative" to open up the international channels of South Asia and Southeast Asia has brought new development opportunities to many enterprises. This time, Yunnan Jianfeng Marketing Department went abroad to seize the opportunity, breaking the previous practice that the company mainly relied on agents for cement export, and achieved a new breakthrough in directly connecting users, which not only increased revenue, but also further expanded the radiation scope of its own marketing network, so as to further expand the scope of going abroad in the future.
2020
07-31
The company's "three" cultivation through the stage of acceptance
Since November 2015 was included in the second batch of "three" cultivation pilot enterprises in Zhejiang Province, the company has carried out a series of related work in depth. On October 19, the implementation of the company's "three" cultivation project from January 2016 to September 2017 passed the phased acceptance organized by Jinhua Economic and Information Commission and Jinhua Finance Bureau. According to the requirements of the "three" cultivation pilot enterprise responsibility letter signed with Zhejiang Province, Jinhua City and Wucheng District, as of the end of September 2017, the company has invested 16.0772 million yuan in related projects, and has achieved remarkable results in improving management, improving automation and informatization level. For example, after the digital system of quality and cost control in the plant extraction workshop of Jianfeng Health Technology Company is put into use, the whole production process can be controlled and traceable, the product quality is more stable, the production safety is effectively guaranteed, the "three wastes" emission is greatly reduced, and the product cost is reduced by 20%. The electronic label system of the pharmaceutical company automatically addresses and accurately locates the drugs in and out of the warehouse, which reduces the error rate of the out and into the warehouse, and the location management can automatically display the information such as the location and quantity of the drugs, which improves the work efficiency of the warehouse logistics and effectively reduces the management cost. The pharmaceutical company's sales management information system integrates sales management, warehouse management, customer management, statistical analysis and other modules, realizes drug sales management and control functions according to the requirements of GMP and GSP specifications, and analyzes drug regions and sales volume through big data, which will judge drug consumption trends faster and more accurately and improve the accuracy of the company's drug sales decisions. Health
2020
07-31
"We were also praised by the traffic police." On September 26, when talking about the civilized travel volunteer activities a few days ago, Li Xuegen of the big pharmacy smiled and was very happy that his work was recognized. Starting from May this year, during the rush hour on the 5th and 20th of each month (weekends and holidays are postponed), there will be a group of volunteers wearing red vests and hats, holding signs with the words "courtesy of zebra crossing, civilized crossing of the road" to divert traffic at many intersections in the city. This is a civilized travel volunteer service activity carried out by Jinhua City to further promote civilized travel and persuade uncivilized behavior. As a civilized unit at the municipal level in Jinhua, Jianfeng Group's duty junction is at the intersection of Bayi North Street and Zhongshan West Road. Before the activity was carried out, as the organizer of the group company, the group office had deep concerns. The activity took a long time and required a lot of manpower. As an enterprise, under the condition of ensuring normal production, it was completed by employees in their spare time. Can it be continued? To this end, Xiang Chongping, the leader in charge of the group company, specially organized a meeting of the directors of the subordinate enterprise offices to mobilize and deploy the matter. The group office also specially established the QQ group of "Peak Civilized Travel Volunteer Service" to release the contents and arrangements of the activities, update the duty situation, and praise the small partners on duty. At the beginning of the activity, colleagues in the headquarters building took the lead in taking up their posts. The first class was Li Hong, Li Xia, Yang Liu and Lei Yuan of the finance department of the group company. Employees of the group office, the peak health experience hall, Qiubin Factory and the international trading company also took up their posts one after another. Other enterprises also took part in an orderly manner according to the duty schedule.
2020
07-31
Daye peak again won the national inspection big contrast "all-excellent award"
A few days ago, daye peak cement co., ltd won the "all-excellent award" in the 16th national cement quality index inspection comparison of "hongchao science and technology cup" organized by the national cement quality supervision and inspection center in 2017 ". The national cement quality index inspection is held every two years. It is the highest level competition in the cement industry. It aims to understand the current quality inspection level of China's cement industry through large-scale comparison, promote various cement inspection departments to improve the inspection quality, and provide accurate data for cement production and use. The results truly reflect the overall inspection level of national cement production enterprises and provincial building materials (cement) inspection stations, it represents the highest level of inspection technology in the cement industry. Over the years, Daye Peak has firmly established the concept of "quality is the life of an enterprise", always puts product quality control in the first place, and conducts daily inspections in strict accordance with the testing items and frequency specified by national standards. actively carry out inspection comparison with provincial and municipal cement quality inspection centers, improve the professional level of inspectors through skill training, and spot check the internal passwords of inspectors every month to strictly ensure the accuracy and reliability of data, to ensure that the quality of the factory cement to meet the market and customer demand, and further enhance the core competitiveness of enterprises. Since it was officially put into production in 2008, Daye Peak has participated in the national cement quality index inspection five times, and has achieved good results. Among them, it won the "All-Excellent Award" in 2009 and the "All-Qualified" in 2011, 2013 and 2015. Unit Award ". (Yang Huiping)
2020
07-31